Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Q-VD-OPh and the Timing of Apoptosome Control
2026-09-28
Q-VD-OPh is a cell-permeable pan-caspase inhibitor that can reveal whether a phenotype depends on downstream caspase execution. This article pairs its mechanistic and experimental uses with new evidence that apoptosomes are transient, spatially organized assemblies, enabling more informative apoptosis research and assay design.
-
Metabolomics Reveals Carbapenemase Resistance Signatures
2026-09-28
A 2025 LC-MS/MS study profiled carbapenemase-producing and non-producing Enterobacterales and identified metabolite signatures that distinguished the groups after six hours of antibiotic-free growth. The findings suggest a route toward faster resistance phenotyping while highlighting that the reported biomarkers are candidates for diagnostic development, not evidence of treatment response or causal resistance mechanisms.
-
Taltirelin Acetate: From Mechanism to Translation
2026-09-27
Taltirelin offers a useful case study in translating neuromodulator pharmacology into testable physiological outcomes. Evidence for sustained tongue motor activation in rats provides a rationale for OSA research, while careful study design must separate this signal from broader neuroprotective and formulation applications.
-
MDV3100: AR Heterogeneity in Prostate Cancer Models
2026-09-26
Use MDV3100 (Enzalutamide) to test androgen receptor dependence, pathway suppression, and treatment response in prostate cancer models. Pair drug exposure with AR-status profiling to distinguish sensitive AR-positive cells from AR-low or AR-negative populations that may persist despite treatment.
-
ROCK Inhibition in Organoid-Era Cancer Research
2026-09-25
Patient-derived medulloblastoma organoids create a valuable setting for asking how cytoskeletal signaling shapes tumor behavior. This article considers where Y-27632 could help test those questions, how to design interpretable perturbation studies, and why its role in these models remains a hypothesis to validate—not a finding of the organoid study.
-
Bardoxolone Methyl: Redox Research Workflows
2026-09-25
Use Bardoxolone methyl to probe Nrf2 activation and NF-kB inhibition in oxidative-stress, inflammation, kidney-injury, and cancer models. This guide turns those mechanisms into a practical workflow while showing how to test—rather than assume—a connection to thioredoxin-dependent replication-stress biology.
-
Beyond ATP Competition: Translating VX-702 Biology
2026-09-24
VX-702 offers a precise way to interrogate p38α MAPK signaling across inflammatory and tissue-injury models. This article connects its reported pharmacology with emerging evidence on activation-loop dephosphorylation, then outlines experiments that can separate established inhibitor effects from mechanisms that still need testing.
-
Pifithrin-α Workflows for p53-Linked Ferroptosis
2026-09-24
Use Pifithrin-α (PFTα) to test whether p53 activity contributes to stress-related cell injury—not simply whether a treatment changes viability. This practical guide adapts a maternal deltamethrin neurotoxicity study into a controlled HT-22 workflow, with assay choices and troubleshooting that separate p53-pathway effects from evidence of ferroptosis.
-
Gingerenone A Restores Sunitinib Sensitivity in RCC
2026-09-23
A 2026 study identifies gingerenone A as an LDHA-associated metabolic inhibitor that suppresses glycolysis and weakens HIF-1α/VEGFA/VEGFR2 signaling in renal cell carcinoma. By combining gingerenone A with sunitinib, the researchers observed synergistic effects in cell models and greater tumor-growth suppression in vivo, including in a sunitinib-resistant setting.
-
Parathyroid Hormone (1-34) Human: Assay Design
2026-09-23
Parathyroid hormone (1-34) (human) is a receptor-active tool for connecting cAMP signaling with bone and kidney disease models. This guide emphasizes exposure-pattern control, assay endpoint selection, and the implications of PTH-driven valvular endothelial-to-mesenchymal transition.
-
Amplex Red in Nanoelectrode Biosensing
2026-09-22
Amplex Red is more than a hydrogen peroxide reporter: paired with immobilized HRP, it becomes a functional readout for enzyme activity on nanoscale electrodes. This article connects fluorogenic chemistry with assay design, spatial biosensing, and rigorous interpretation of redox signals.
-
Meropenem Trihydrate and the Metabolomic Resistance Map
2026-09-22
Meropenem trihydrate is more than a broad-spectrum carbapenem antibiotic: used as a defined experimental pressure, it can help translational researchers connect cell-wall pharmacology with the metabolic signatures of carbapenem resistance. This article interprets recent LC-MS/MS evidence and translates it into practical, reproducible research strategy.
-
Amplex Red: ATX Assay Workflow & Optimization
2026-09-21
Learn how Amplex Red converts enzyme-coupled hydrogen peroxide production into a quantitative fluorescence readout for autotaxin inhibitor discovery, ROS studies, and redox biology. This practical guide combines cascade design, screening logic, interference controls, and troubleshooting for reproducible microplate assays.
-
Sitagliptin Phosphate Monohydrate: Assay Logic
2026-09-21
Sitagliptin phosphate monohydrate can do more than establish DPP-4 inhibition in metabolic studies. This article presents a causal assay framework that separates incretin stabilization from intestinal stretch signaling, enabling sharper interpretation of gut–brain and glucose-homeostasis experiments.
-
Salvianolic Acid B Targets LH2 in Pulmonary Fibrosis
2026-09-20
The reference study identifies Salvianolic acid B, also known as Dan Shen Suan B, as a compound that suppresses lysyl hydroxylase 2 expression and reduces pathological collagen remodeling in pulmonary fibrosis models. Its significance lies in connecting LH2-dependent collagen cross-linking with epithelial and fibroblast activation, while providing a practical framework for testing matrix-centered antifibrotic mechanisms.